Grifols (NASDAQ:GRFS) Shares Gap Up – Should You Buy?

Grifols, S.A. (NASDAQ:GRFS)’s stock price gapped up before the market opened on Friday . The stock had previously closed at $6.52, but opened at $6.81. Grifols shares last traded at $6.79, with a volume of 66,413 shares traded.

Analysts Set New Price Targets

Separately, Morgan Stanley started coverage on Grifols in a research note on Wednesday, February 12th. They issued an “overweight” rating on the stock.

Grifols Stock Performance

The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. The stock has a market cap of $4.63 billion, a P/E ratio of 5.77 and a beta of 0.41. The firm’s 50-day moving average is $7.49 and its two-hundred day moving average is $7.89.

Institutional Investors Weigh In On Grifols

Several institutional investors and hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. raised its holdings in Grifols by 7.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 31,543 shares of the biotechnology company’s stock valued at $280,000 after buying an additional 2,301 shares in the last quarter. HighTower Advisors LLC raised its stake in shares of Grifols by 12.5% in the 3rd quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 1,546 shares in the last quarter. Quantinno Capital Management LP raised its stake in shares of Grifols by 11.6% in the 3rd quarter. Quantinno Capital Management LP now owns 104,545 shares of the biotechnology company’s stock valued at $928,000 after acquiring an additional 10,830 shares in the last quarter. Stifel Financial Corp acquired a new stake in Grifols in the 3rd quarter worth approximately $1,043,000. Finally, Jane Street Group LLC bought a new stake in Grifols during the third quarter worth approximately $363,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.